Xenometrix launches new kit for genotoxicity analysis

Thursday, January 15, 2026 @ 12:00 am

Xenometrix has launched the Rapid Micronucleus MoA (Mode of Action) Telomere Centromere Kit, a next-generation assay that accelerates and improves mechanistic genotoxicity analysis.

Key Features

Rapidly distinguishes between aneugenic (chromosome loss) and clastogenic (chromosome breakage) events.
Uses advanced FISH probes and an optimized workflow for high-contrast telomere and centromere signals.
Streamlined protocol reduces hands-on time and complexity, making it suitable for routine.
Validation of Results: Provides greater classification confidence than conventional micronucleus assays.
Supports faster, clearer mechanistic data and decision-making.
Aligns with existing regulatory guidelines OECD TG487 and with new regulatory expectations for mechanistic clarity in genotoxicity testing.
Now available for research use directly from Xenometrix.
For more information on the Kit contact us: [email protected]

You may also be interested in

Beware of fraudulent emails impersonating the Swiss Biotech Association

Don’t fall for fraudsters! Cyber criminals can reach you easily with today's communication means. We regularly detect fraudulent emails attempting to steal your passwords — both personal and for our systems — through phishing attacks. Smishing (SMS, text messages) or vishing (phone calls) are also a common way to retrieve information from you. With seemingly legitimate messages the criminals
October 8, 2024

Nouscom reports new findings on cancer interception

Lynch Syndrome (LS) is a common hereditary condition that significantly increases the lifetime risk of developing multiple cancers NOUS-209 is an off-the-shelf cancer immunotherapy designed to induce T cells against neoantigens present in tumors and precancer lesions in LS carriers Publication in Nature Medicine underscores significance of NOUS-209 clinical data and its innovative approach to inte
January 16, 2026

Newron: Evenamide off to a flying start - new patent & phase III trial

January 13, 2026

Cosmo: A clear step forward on Vision 2030

January 13, 2026

Pharvaris outlines 2026 strategic priorities

Topline data from CHAPTER-3, a pivotal study of deucrictibant for prophylactic treatment of HAE attacks, anticipated in 3Q2026 Preparation of NDA dossier of deucrictibant for on-demand treatment of HAE attacks ongoing; timeline remains on-track for filing in 1H2026 Recruitment ongoing in CREAATE, a pivotal study of deucrictibant for the prophylactic and on-demand treatment of AAE-C1INH attacks Est
January 12, 2026

Oculis: FDA breakthrough therapy designation for optic neuritis

Breakthrough Therapy Designation granted to Privosegtor, a neuroprotective candidate, for the treatment of optic neuritis Privosegtor is advancing in the registrational PIONEER program across 2 key optic neuropathies, representing an unaddressed potential market of $7 billion in the U.S. Privosegtor achieved an average gain in Low Contrast Visual Acuity (LCVA) of 18 letters compared to IV steroi
January 6, 2026

Xenometrix launches new kit for genotoxicity analysis

Company

You may also be interested in

Beware of fraudulent emails impersonating the Swiss Biotech Association

Nouscom reports new findings on cancer interception

Newron: Evenamide off to a flying start - new patent & phase III trial

Cosmo: A clear step forward on Vision 2030

Pharvaris outlines 2026 strategic priorities

Oculis: FDA breakthrough therapy designation for optic neuritis